Rasonque (daraxonrasib)
Revolution Medicines (RVMD)
ApprovedAug 26, 2026
Marketer take
A targeted option in metastatic pancreatic cancer, one of oncology's hardest-to-treat settings, so expect high oncologist attention and fast pathway reviews at cancer centers and community practices.
- Sponsor company
- Revolution Medicines (RVMD)
- Indication
- To treat metastatic pancreatic cancer
- Therapeutic area
- Oncology
- Event
- FDA approval
- Date
- Aug 26, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?